DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR INULIN AND SODIUM CHLORIDE
Clinical Trials for Inulin And Sodium Chloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00005107 | Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia | Unknown status | National Center for Research Resources (NCRR) | Phase 1 | 1969-12-31 | This study is to determine whether a compound, nitric oxide, made within the body, is the factor responsible for the changes in blood pressure and renal (kidney) functions that may occur during the course of cirrhosis. Patients with cirrhosis (liver scarring which causes poor liver function) will be eligible to participate. A group of healthy subjects will also be studied to compare the effects of the treatment to patients with cirrhosis and to confirm safety. A total number of 30 patients with cirrhosis and 10 healthy subjects will be enrolled in the study. |
| NCT00240045 | The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction | Completed | Novartis | Phase 2/Phase 3 | 2005-10-01 | We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are mediated in part by diminished circulatory volume and that treatment with midodrine, octreotide and albumin can improve renal and patient outcomes by restoring effective circulating volume and systemic perfusion. Our primary objective is to assess change in creatinine clearance using inulin. We will enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR, albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before, during, and after initiation of drug and compared. |
| NCT00240045 | The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction | Completed | University of Alberta | Phase 2/Phase 3 | 2005-10-01 | We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are mediated in part by diminished circulatory volume and that treatment with midodrine, octreotide and albumin can improve renal and patient outcomes by restoring effective circulating volume and systemic perfusion. Our primary objective is to assess change in creatinine clearance using inulin. We will enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR, albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before, during, and after initiation of drug and compared. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Inulin And Sodium Chloride
Condition Name
Condition MeSH
Clinical Trial Locations for Inulin And Sodium Chloride
Trials by Country
Clinical Trial Progress for Inulin And Sodium Chloride
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Inulin And Sodium Chloride
Sponsor Name
| Sponsor Name for Inulin And Sodium Chloride | |
| Sponsor | Trials |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| Centre Hospitalier Universitaire Vaudois | 2 |
| Rabin Medical Center | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
